***Background.*** MenACWY-CRM vaccine was immunogenic in 2--10 year-old children in 1- and 2-dose schedules. As only limited data is available on antibody persistence we assessed bactericidal antibodies 5 years after primary vaccination and response to a booster dose, compared with age-matched vaccine-naïve controls (clinicaltrials.gov NCT01823536).

***Methods.*** We enrolled two groups of 7--10 year-olds after 1 (n = 101) or 2 (n = 73) doses of MenACWY-CRM as 2--5 year-olds, and a group of 11--15 year-olds after 1 dose (n = 66) as 6--10 year-olds, with age-matched naïve-controls (n = 120 and 101). We measured serum bactericidal activity with human complement (hSBA) at baseline and 30 days after a booster or first MenACWY-CRM vaccination. Local and systemic reactions and any adverse events were recorded.

***Results.*** Five years postvaccination levels of antibodies were still higher than controls in the three vaccinated groups, who displayed anamnestic responses to a booster dose, with 99--100% having hSBA titers ≥ 8 against all four serogroups.

             Percentages with hSBA ≥ 8 \[95%CI\]                                                                                                                                                                         
  ---------- ------------------------------------- --------------------- ------------------- --------------------- ------------------- ------------------- ------------------- --------------------- ------------------- -------------------
  **Time**   **Pre**                               **Post**              **Pre**             **Post**              **Pre**             **Post**            **Pre**             **Post**              **Pre**             **Post**
  *n/N*      *13/99*                               *99/99*               *5/71*              *68/69*               *0/119*             *88/118*            *15/65*             *64/64*               *5/101*             *80/99*
  **A**      **13** \[7, 21\]                      **100** \[96, 100\]   **7** \[2, 16\]     **99** \[92, 100\]    **0** \[0, 3\]      **75** \[66, 82\]   **23** \[14, 35\]   **100** \[94, 100\]   **5** \[2, 11\]     **81** \[72, 88\]
  *n/N*      *32/99*                               *98/98*               *34/72*             *71/71*               *26/119*            *96/118*            *37/65*             *64/64*               *21/100*            *85/99*
  **C**      **32** \[23, 42\]                     **100** \[96, 100\]   **47** \[35, 59\]   **100** \[95, 100\]   **22** \[15, 30\]   **81** \[73, 88\]   **57** \[44, 69\]   **100** \[94, 100\]   **21** \[13, 30\]   **86** \[77, 92\]
  *n/N*      *73/99*                               *99/99*               *60/72*             *69/69*               *62/119*            *110/118*           *52/65*             *64/64*               *55/101*            *91/99*
  **W**      **74** \[64, 82\]                     **100** \[96, 100\]   **83** \[73, 91\]   **100** \[95, 100\]   **52** \[43, 61\]   **93** \[87, 97\]   **80** \[68, 89\]   **100** \[94, 100\]   **54** \[44, 64\]   **92** \[85, 96\]
  *n/N*      *48/99*                               *98/98*               *37/73*             *71/71*               *28/119*            *101/119*           *35/65*             *63/63*               *37/101*            *80/99*
  **Y**      **48** \[38, 59\]                     **100** \[96, 100\]   **51** \[39, 63\]   **100** \[95, 100\]   **24** \[16, 32\]   **85** \[77, 91\]   **54** \[41, 66\]   **100** \[94, 100\]   **37** \[27, 47\]   **81** \[72, 88\]

Reactogenicity was similar across groups, 50--67% and 27--36% of children had mild to moderate solicited local and systemic reactions. No vaccine-related SAEs were reported.

***Conclusion.*** 5 years after 1- and 2-dose MenACWY-CRM vaccination in 2--10 year-olds, half or more of the children still had persistent antibodies against serogroups C, W and Y with robust responses to a booster dose.
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